期刊文献+

绝经后骨质疏松症相关骨代谢指标、细胞因子IGF-1的临床观察 被引量:21

The clinical observation of bone metabolic index and cytokine IGF-1 in postmenopausal osteoporosis patients
下载PDF
导出
摘要 目的检测绝经后骨质疏松症(PMOP)患者体内的骨代谢指标、细胞因子的水平变化。为临床早期防治骨质疏松提供有力依据。方法选取长春地区45-69岁绝经后女性108例,按照WHO标准将入选女性分为骨密度正常者组46例,骨密度减低者组30例,骨质疏松组32例,双能X线吸收法DEXA测定2-4腰椎BMD;测定108例受试者血清雌二醇(E2)、胰岛素样生长因子-1(IGF-1)、骨碱性磷酸酶(BAP)及血清骨保护素(OPG)、核因子-k受体活化因子配体(RANKL)的水平,并进行相关性分析。结果 PMOP组、骨量减低组和正常对照组之间E2、OPG、RANKL、BAP、IGF-1差异均有统计学意义(P<0.05、P<0.01)。PMOP组BAP水平明显高于骨量减低组及正常对照组(P<0.01),E2水平明显低于骨量减低组(P<0.01)及正常对照组(P<0.05)。骨量减低组与正常对照组之间BAP和E2水平差异无统计学意义(P>0.05)。通过综合分析,E2与IGF-1呈显著正相关(r=0.562,P<0.01),与BAP呈负相关[r值分别为-0.15(P=0.034);RANKL与BAP呈正相关(r=0.224、P=0.036)。结论 E2、IGF-1、OPG、BAP、RANKL在PMOP临床诊治中有帮助,可作为其辅助指标。 Objective To examine levels of bone metabolic index and cytokine IGF-1 in postmenopausal women,and provide the reference for clinical early prevention of osteoporosis.Methods The levels of serum osteoprotegerin (OPG),nuclear factor-k beta receptor activator ligand (RANKL),bone alkaline phosphatase (BAP),estradiol (E2), cytokine IGF-1 were determined in 32 patients with PMOP,30patients with bone mass reducing and 46 subjects with normal bone mass(control group).Partial correlation analysis was used for some of the indicators excluding age and E2,and the correlation was analyzed.Results A statistical significance in E2,OPG,RANKL,BAP and IGF- 1 levels was observed in patient groups and control group(P 〈0.05,P 〈0.01).BAP levels of PMOP group were higher than those of bone mass reducing and control groups(P 〈0.01).However,E2 levels were lower than those of bone mass reducing group(P 〈0.01)and control group(P 〈0.05).There was no significant difference in E2 and BAP levels be-tween bone mass reducing group and control group(P 〉0.05).IGF-1 with E2 showed a significant positive correlation (r=0.562 and ,P 〈0.01),and IGF-1 was negatively correlated significantly with BAP(r=-0.15 and ,P =0.034), there was a positive correlation between RANKL and BAP (r=0.224,P =0.036).Conclusion The levels of BAP,E2 and IGF-1 may be indices of clinical diagnosis and treatment of PMOP.
出处 《中国实验诊断学》 2014年第6期919-921,共3页 Chinese Journal of Laboratory Diagnosis
关键词 骨碱性磷酸酶 血清骨保护素 核因子-k受体活化因子配体(RANKL) 胰岛素样生长因子-1 血清雌二醇 绝经后骨质疏松症 bone alkaline phosphatase osteoprotegerin nuclear factor-k beta receptor activator ligand Cytokine estradiol Postmenopausal osteoporosis
  • 相关文献

参考文献6

  • 1Manolagas SC. Birth and death of bone ceiis: basic regulatory mechanisms and implications for the patho genesis and treatment of osteoporosis[J]. Endocr Rev,2000,21(8) :115. 被引量:1
  • 2GALI JC. Osteoporosis[J]. Acta or top Bras,2001,9(6) :53. 被引量:1
  • 3Vlimki MJ, Farrerons-Minguella J, Halse J, et al. Effects of risedr- onate 5mg/d on bone mineral density and bone turnover markers in late postmenopausal women with osteopenia:a multinational,24-month, randomized, double-blind, placebo-cdntrolled, parallel- group, phase III trial[J]. Clin Ther, 2007,29 (9) : 1937. 被引量:1
  • 4Kaufman J J, Luo G, Siffert RS. Ultrasound simulation in bone[J]. IEEE Trans Ultrason Ferroelectr Freq Control, 2008, 55 (6): 1205. 被引量:1
  • 5刘红,廖二元,伍贤平,张红,罗湘杭,谢辉,曹行之,刘石平.正常女性与年龄相关的骨转换生化指标和骨密度的关系[J].中华内科杂志,2004,43(11):805-809. 被引量:27
  • 6吕宽,刘春雨,路英菊.PMO患者血清E_2、IL-6及IGF-Ⅰ水平的临床观察[J].放射免疫学杂志,2006,19(5):364-366. 被引量:4

二级参考文献23

  • 1Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta,2001,313:95-105. 被引量:1
  • 2Rogers A, Hannon RA, Eastell R. Biochemical makers as predictors of rates of bone loss after menopause. J Bone Miner Res,2000,15: 1398-1404. 被引量:1
  • 3Chaki O, Yoshikata I, Kikuchi R, et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res, 2000,15:1537-1544. 被引量:1
  • 4Tromp AM, Ooms ME, Popp-Snijders C, et al. Predictors of fractures in elderly women. Osteoporos Int,2000,11:134-140. 被引量:1
  • 5Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res,2000,15:1526-1536. 被引量:1
  • 6Tanko LB, Felsenberg D, Czerwinski E, et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med,2003 ,254:159-167. 被引量:1
  • 7Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res,2002,17: 1904-1912. 被引量:1
  • 8Brown JP, Delmas PD, Malaval L, et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet,1984,1:1091-1093. 被引量:1
  • 9Gomez B Jr, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem,1995,41:1560-1566. 被引量:1
  • 10Hanson DA, Weis MA, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res,1992,7:1251-1258. 被引量:1

共引文献29

同被引文献197

引证文献21

二级引证文献148

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部